Skip to main content

Table 3 Tumor parameters for patients with a clear-cell tumor, also stratified by VHL mutation status

From: Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands cohort study

  All tumors (N = 188) VHL mutated tumors (N = 115) Wildtype tumors (N = 73)   
  N % N % N % χ2 p-value †
T (TNM*)         
1 5 2.7 4 3.5 1 1.4   
2 93 49.5 55 47.8 38 52.1   
3A 35 18.6 20 17.4 15 20.6   
3B 50 26.6 34 29.6 16 21.9   
4 2 1.1 1 0.9 1 1.4 0.18§** 0.67
X 3 1.6 1 0.9 2 2.7   
N (TNM*)         
0 126 67.0 78 67.8 48 65.8   
1 7 3.7 6 5.2 1 1.4   
2 7 3.7 5 4.4 2 2.7 1.51¶** 0.22
X 48 25.5 26 22.6 22 30.1   
M (TNM*)         
0 131 69.7 77 67.0 54 74.0   
1 26 13.8 18 15.7 8 11.0 0.99** 0.32
X 31 16.5 20 17.4 11 15.1   
Stage (TNM*)         
1 5 2.7 4 3.5 1 1.4   
2 83 44.2 46 40.0 37 50.7   
3 66 35.1 42 36.5 24 32.9   
4 32 17.0 22 19.1 10 13.7 1.41§** 0.24
X 2 1.1 1 0.9 1 1.4   
Nuclear grading †‡         
I 46 24.5 27 23.5 19 26.0   
II 67 35.6 43 37.4 24 32.9   
III 48 25.5 29 25.2 19 26.0   
IV 27 14.4 16 13.9 11 15.1 0.43 0.94
  1. * Based on pathological TNM unless unknown, then clinical TNM (UICC, 1987) was used [17]
  2. † Based on the review by one experienced pathologist (CAHK)
  3. ‡ According to Fuhrman [19]
  4. §1–2 vs. 3–4
  5. ¶1–2 vs. 0
  6. ** Excludes "X (unknown) " category